Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

@article{Higashi2002AssociationBC,
  title={Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.},
  author={Mitchell K. Higashi and David L. Veenstra and L Midori Kondo and Ann K. Wittkowsky and Sengkeo L. Srinouanprachanh and Federico M. Farin and Allan E Rettie},
  journal={JAMA},
  year={2002},
  volume={287 13},
  pages={1690-8}
}
CONTEXT Warfarin is a commonly used anticoagulant that requires careful clinical management to balance the risks of overanticoagulation and bleeding with those of underanticoagulation and clotting. The principal enzyme involved in warfarin metabolism is CYP2C9, and 2 relatively common variant forms with reduced activity have been identified, CYP2C9*2 and CYP2C9*3. Patients with these genetic variants have been shown to require lower maintenance doses of warfarin, but a direct association… CONTINUE READING
Highly Influential
This paper has highly influenced 22 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
359 Citations
42 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 359 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Oral anti- coagulants. Chest

  • J Hirsch, DE Dalen, D Anderson
  • 2001
Highly Influential
3 Excerpts

The Hardy- Weinberg principle. In: Fundamentals of Genetic Epi- demiology

  • MJ Khoury, TH Beaty, BH. Cohen
  • 1993
Highly Influential
3 Excerpts

Thrombosis. In: Koda-Kimble MA, Young LY, eds. Applied Therapeutics: The Clinical Use of Drugs

  • AK Wittkowsky
  • 7th ed. Philadelphia,
  • 2001
1 Excerpt

Similar Papers

Loading similar papers…